XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

NASDAQ:XOMA • US98419J2069

26.25 USD
+1.85 (+7.58%)
Last: Feb 20, 2026, 12:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, XOMA scores 5 out of 10 in our fundamental rating. XOMA was compared to 521 industry peers in the Biotechnology industry. While XOMA is still in line with the averages on profitability rating, there are concerns on its financial health. XOMA is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • XOMA had positive earnings in the past year.
  • In the past year XOMA had a positive cash flow from operations.
  • In multiple years XOMA reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • XOMA has a better Return On Assets (3.75%) than 89.83% of its industry peers.
  • Looking at the Return On Equity, with a value of 9.14%, XOMA belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 3.31%, XOMA belongs to the top of the industry, outperforming 90.79% of the companies in the same industry.
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROIC 3.31%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • XOMA's Profit Margin of 20.96% is amongst the best of the industry. XOMA outperforms 93.86% of its industry peers.
  • The Operating Margin of XOMA (20.92%) is better than 95.20% of its industry peers.
Industry RankSector Rank
OM 20.92%
PM (TTM) 20.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMA is destroying value.
  • Compared to 1 year ago, XOMA has more shares outstanding
  • XOMA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, XOMA has a worse debt to assets ratio.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.61, we must say that XOMA is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.61, XOMA is not doing good in the industry: 60.46% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.87 indicates that XOMA is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.87, XOMA is doing worse than 72.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z -4.61
ROIC/WACC0.37
WACC8.98%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • XOMA has a Current Ratio of 3.91. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.91, XOMA perfoms like the industry average, outperforming 47.22% of the companies in the same industry.
  • XOMA has a Quick Ratio of 3.91. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
  • XOMA has a Quick ratio (3.91) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.91
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 135.71% over the past year.
  • The Revenue has grown by 103.96% in the past year. This is a very strong growth!
  • Measured over the past years, XOMA shows a quite strong growth in Revenue. The Revenue has been growing by 9.17% on average per year.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%

3.2 Future

  • Based on estimates for the next years, XOMA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
  • XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.64% yearly.
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • XOMA is valuated quite expensively with a Price/Earnings ratio of 35.00.
  • Compared to the rest of the industry, the Price/Earnings ratio of XOMA indicates a rather cheap valuation: XOMA is cheaper than 92.71% of the companies listed in the same industry.
  • XOMA's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.09.
  • A Price/Forward Earnings ratio of 83.49 indicates a quite expensive valuation of XOMA.
  • Based on the Price/Forward Earnings ratio, XOMA is valued cheaper than 88.48% of the companies in the same industry.
  • XOMA is valuated expensively when we compare the Price/Forward Earnings ratio to 27.98, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 35
Fwd PE 83.49
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • XOMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XOMA is cheaper than 92.90% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 29.85
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • XOMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as XOMA's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y46.72%
EPS Next 3Y37.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • XOMA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (2/20/2026, 12:00:38 PM)

26.25

+1.85 (+7.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-05
Inst Owners67.66%
Inst Owner Change1.21%
Ins Owners1.79%
Ins Owner Change6.97%
Market Cap324.98M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts84
Price Target65.79 (150.63%)
Short Float %8.65%
Short Ratio2.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)0%
PT rev (3m)-7.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100.88%
EPS NY rev (1m)7.34%
EPS NY rev (3m)115.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.15%
Valuation
Industry RankSector Rank
PE 35
Fwd PE 83.49
P/S 6.9
P/FCF N/A
P/OCF 59.42
P/B 3.01
P/tB 5.13
EV/EBITDA 29.85
EPS(TTM)0.75
EY2.86%
EPS(NY)0.31
Fwd EY1.2%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.68%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.22
PEG (5Y)N/A
Graham Number12.13
Profitability
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROCE 4.2%
ROIC 3.31%
ROICexc 4.14%
ROICexgc 5.42%
OM 20.92%
PM (TTM) 20.96%
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA 7.77
Cap/Depr 880.03%
Cap/Sales 42.84%
Interest Coverage 0.83
Cash Conversion 45.03%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.91
Altman-Z -4.61
F-Score6
WACC8.98%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.59%
EBIT Next 3Y49.29%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A

XOMA ROYALTY CORPORATION / XOMA FAQ

Can you provide the ChartMill fundamental rating for XOMA ROYALTY CORPORATION?

ChartMill assigns a fundamental rating of 5 / 10 to XOMA.


What is the valuation status for XOMA stock?

ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORPORATION (XOMA). This can be considered as Fairly Valued.


How profitable is XOMA ROYALTY CORPORATION (XOMA) stock?

XOMA ROYALTY CORPORATION (XOMA) has a profitability rating of 5 / 10.


How financially healthy is XOMA ROYALTY CORPORATION?

The financial health rating of XOMA ROYALTY CORPORATION (XOMA) is 3 / 10.


What is the earnings growth outlook for XOMA ROYALTY CORPORATION?

The Earnings per Share (EPS) of XOMA ROYALTY CORPORATION (XOMA) is expected to grow by 157.93% in the next year.